Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study - Wikidata - awgldk - TriplyDB

Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

http://www.wikidata.org/entity/Q28211801

about

Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy.Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer Survival after initial lung metastasectomy for metastatic colorectal cancer in the modern chemotherapeutic era BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study.Cancer therapy and cardiovascular risk: focus on bevacizumab.Prognostic importance of some clinical and therapeutic factors for the effect of portal vein embolization in patients with primarily inoperable colorectal liver metastases.Targeted therapeutic agents for colorectal cancer.Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases.Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells.Synchronous resection of colorectal primary and hepatic metastasis.Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases.Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States.Neither creatinine nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents.Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy.Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.Research progress on common adverse events caused by targeted therapy for colorectal cancer.

P2860

Q33477125-98A55CE5-F08C-4476-9A44-72A58AB5CCA7 Q33484460-DD4E13E7-5DFF-4801-8DEA-EB735122ACA2 Q33655018-E12AE2BC-39EE-4C78-AD9C-D7BDD840A37D Q33906044-01EBBCE1-D1D3-4A5B-A347-EF018665FE04 Q34101611-26882331-FCD8-4DF3-BCF8-16180DA71E70 Q34348270-87CEC4B7-AC74-46C1-8927-19EB8EDCFAF7 Q35083070-269C970C-25EB-48BB-B2BB-247507697076 Q35703835-4B84460C-557D-48BC-B668-6B5508CD75AB Q36686108-8EF74AC0-AFAB-4A0D-9781-F07FCB923894 Q37158228-B75B5212-6CD8-492F-A58D-95C612405E9F Q37688711-283F5DA9-721B-40F8-816F-9B52E8122BC3 Q37821845-46E79BD0-CD5F-49F7-B740-242799AF1B73 Q38220817-50BB9E9B-29E2-432E-8646-32893C2D4414 Q39018153-B4FE4593-F604-4C93-B00B-933558E568DC Q39112034-13830E5C-B309-487B-BBD8-012867A396D6 Q41810739-68DB6034-473F-49A2-8ED3-8F423B38F54E Q41830454-FAA2FE35-BCB0-4077-BE83-8C610EA3E87D Q45104926-9A52526D-D52F-4CAD-823E-124E4D8131DC Q49097109-F1C2D80F-D323-4FDB-9218-EA1561F70CB8 Q50672514-DDC0F9A8-71A9-4AFD-AC33-76C11BDF8FB0 Q51804221-BA2D5CF8-5A49-427C-A926-66AD71AD1048 Q55360813-8B6A08A1-D0F2-40A8-AD16-560AA5E0DF72

P2860

Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

http://www.wikidata.org/entity/Q28211801

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Front-line bevacizumab in comb ...... : a multicenter phase II study

@ast

Front-line bevacizumab in comb ...... : a multicenter phase II study

@en

Front-line bevacizumab in comb ...... : a multicenter phase II study

@nl

type

label

Front-line bevacizumab in comb ...... : a multicenter phase II study

@ast

Front-line bevacizumab in comb ...... : a multicenter phase II study

@en

Front-line bevacizumab in comb ...... : a multicenter phase II study

@nl

prefLabel

Front-line bevacizumab in comb ...... : a multicenter phase II study

@ast

Front-line bevacizumab in comb ...... : a multicenter phase II study

@en

Front-line bevacizumab in comb ...... : a multicenter phase II study

@nl

P1433

Q28211801-6CCFAF27-3ECF-4DF1-90F1-34BCFE766A4E

P1476

Q28211801-A8DF2A8E-0192-4EA9-987F-EEB359F44CC9

P2093

Q28211801-042375E8-46A1-49AA-93EA-9144203D07FA

Q28211801-0588DB4D-D36E-45B1-9841-B6B5D956FE1F

Q28211801-2AFBD828-DB12-4826-AADD-DE4690A4B9D8

Q28211801-2E1D2728-C244-46C0-9308-72AE94782459

Q28211801-3988465E-AD03-4D2B-98CE-279E8B23E07E

Q28211801-4EFA7643-11C8-4F81-8CB2-3D5E56170EB7

Q28211801-51210BF7-E6DC-4A6E-AE94-97428434D628

Q28211801-5CC12086-DC46-4389-933B-DCD47B655308

Q28211801-7A6518E2-17BB-47E8-AD06-20E2B24FAE6A

Q28211801-90758A75-E128-4C85-8541-0D30F7F34646

P2860

Q28211801-03B1DFD0-A588-4DD8-9201-D38F778DAB45

Q28211801-0787BA15-8001-4130-A31A-3BE50A4C8B65

Q28211801-1E0D532D-2A60-4534-BDE1-10EA40E49458

Q28211801-20462364-C62F-4F59-8125-F3A5E0798DC3

Q28211801-21C08E29-5BC7-4E88-94E9-2810504E5761

Q28211801-2542392E-7717-4B12-9DEB-D8A3151CED3C

Q28211801-3C1787BD-58A5-4EFB-9957-97BBA27B86D0

Q28211801-3EB1E60A-D076-4B7C-A21F-E3BE9F73F246

Q28211801-9963EB35-ECBE-4FD9-A92E-26B74811706A

Q28211801-A37E0F8B-AE00-4D72-A082-236D3846DB5C

P2888

Q28211801-3AD75BB9-CE17-42A6-BE24-807DEF85EFAF

P304

Q28211801-FF519903-B4E8-49C0-913A-B9B98B491154

P31

Q28211801-8A8834A1-9327-4362-8BC5-21F6C06D9D1A

P356

Q28211801-8D690A1C-1310-4163-9761-0BDA4ACCA264

P407

Q28211801-DC0CB72C-A684-4457-B7D0-0BA6111978A8

P433

Q28211801-FE105FCB-828D-4AC9-9D37-2FA06AB321B5

P478

Q28211801-3675541B-90E5-46A5-9BF2-4C67EC0D223D

P577

Q28211801-4A62D040-568E-4D92-B804-9660FBF9CF45

P5875

Q28211801-22FF94A4-45CE-46EA-951B-600760EA980F

P6179

Q28211801-17D92BCA-37FE-449F-B5F1-00CA65801128

P698

Q28211801-D75B5F0A-9379-4E28-8626-A12D6C56DF7F

P921

Q28211801-B20FDB6B-A0FC-4A39-B418-636BC3060077

Q28211801-BA267135-5848-4784-A1A1-4836EC565BBD

Q28211801-D9E765A8-6A9D-42DA-8E30-330B19A262EE

P932

Q28211801-DFC70A63-5889-42B3-9F20-6262BF2D1F9C

P356

P1433

P1476

Front-line bevacizumab in comb ...... : a multicenter phase II study

@en

P2093

Adam Chatzidakis

http://www.w3.org/2001/XMLSchema#string

Antonia Kalykaki

http://www.w3.org/2001/XMLSchema#string

Athanasios Kotsakis

http://www.w3.org/2001/XMLSchema#string

Charalambos Christophylakis

http://www.w3.org/2001/XMLSchema#string

Christos Emmanouilides

http://www.w3.org/2001/XMLSchema#string

Dimitris Mavroudis

http://www.w3.org/2001/XMLSchema#string

Eleni Diamandidou

http://www.w3.org/2001/XMLSchema#string

Georgia Sfakiotaki

http://www.w3.org/2001/XMLSchema#string

John Souglakos

http://www.w3.org/2001/XMLSchema#string

Kostas Kalbakis

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Global cancer statistics, 2002

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.

P2888

P304

91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-7-91

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6299336

http://www.w3.org/2001/XMLSchema#string

P6179

1048755655

http://www.w3.org/2001/XMLSchema#string

P698

17537235

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

multicenter trial

P932

1894803

http://www.w3.org/2001/XMLSchema#string